No attachments available.
R--Confirmatory Assays and Safety Pharmacology
Contact and place of performance
Growney, Matthew
Not specified
The EPA is using phenotypic and genomic screening to identify chemical bioactivity leading to hypotheses about chemical mechanism of action (MOA). In order to test MOA hypotheses, EPA requires access to a broad variety of in vitro, target-based assays and panels including binding, enzymatic and functional cellular assay formats.
The Environmental Protection Agency (EPA) Cincinnati Acquisition Division issued this award notice for solicitation 68HERC21R0026 to support research involving confirmatory assays and safety pharmacology. The agency utilizes phenotypic and genomic screening to identify chemical bioactivity, which leads to the development of hypotheses regarding chemical mechanisms of action (MOA). To test these MOA hypotheses, the EPA requires access to a diverse range of in vitro, target-based assays and panels, including binding, enzymatic, and functional cellular assay formats.
This requirement is categorized under NAICS 541715 for Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and PSC R799 for SUPPORT- MANAGEMENT: OTHER. The award notice was published and last updated on December 21, 2021, with Matthew Growney serving as the point of contact. There are zero attachments associated with this notice.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.